Document is current
Any future updates will be listed below
-
Authors
Rometsch, Elke
Thuresson, Per-Olof https://orcid.org/0009-0008-8624-2110
Hurst, Noémie
Eule, Eckhart
Bachmeier, Isabel
Blanchard, Benoit
Sahel, José-Alain
Audo, Isabelle
-
Funding
Funding for this research was provided by:
Roche (Roche)
- License Information
-
More Information
Article History
Received: 23 April 2024
Accepted: 2 April 2025
First Online: 11 August 2025
Declarations
:
: All participants provided signed informed consent forms for participation in the present study. Ethics approval was obtained from the “comité de protection des personnes sud-ouest et outre-mer 2” (IRB tracking number 2-20-123 id10393).
: The informed consent, signed by each participant, included information about potential publications.
: Elke Rometsch, Noémie Hurst, Eckhart Eule, Isabel Bachmeier and Per-Olof Thuresson were employees of F. Hoffmann-La Roche at the time of study conduct. Isabelle Audo is a consultant for Novartis and Janssen. José-Alain Sahel is a consultant/contractor of Avista Therapeutics and Tenpoint, holds stocks or stock options of GenSight Biologics, Sparing Vision, Prophesee, Chronolife, Tilak Healthcare, VegaVect, Inc., Avista, Tenpoint, SharpEye, Celanese and Netramind, is a member of the scientific advisory board of the Gilbert Foundation, Foundation Fighting Blindness, Institute of Ophthalmology Basel, and Senses Institute Lausanne, and holds patents for Allotopic Expression, Rod-derived Cone Viability Factor and related patents.
